Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,556.37
(
-0.37%
)
US TECH 100
23,578.80
(
0.25%
)
Dow Jones
46,124.06
(
-0.18%
)
Brent Oil
96.50
(
-0.30%
)
Bitcoin
70,337.00
(
-0.79%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 152129

Monday, 11/12/2012 11:12:19 PM

Monday, November 12, 2012 11:12:19 PM

Post# of 257275
BMY’s 3-DAA cocktail shows 94% SVR12 for 12-week arm in treatment-naïve genotype-1 HCV:

http://finance.yahoo.com/news/investigational-triple-daa-regimen-daclatasvir-203000008.html

The three drugs in the cocktail are Daclatasvir (NS5A), Asunaprevir (PI), and BMS-791325 (non-nuke).

The 94% SVR12 rate in the 12-week arm was 15 of 16 patients. This trial also has a 24-week arm for which SVR12 data have not yet been reported, but SVR*4* was 94% (also 15 of 16).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now